肺纤维化睡眠评估与夜间低氧血症的临床实践与研究优先事项:国际利益相关者参与研究
该研究通过混合方法在线调查和焦点小组,纳入68例肺纤维化患者和73名来自29个国家的医护人员,评估睡眠与夜间低氧血症的临床实践及研究优先事项。结果显示51%患者曾接受睡眠评估,未评估者中75%主张常规纳入;医护中64%常规或按指征评估。双方共同将治疗夜间低氧血症对症状负担(含健康相关生活质量)的影响列为最高研究优先事项,并将健康相关生活质量作为夜间氧疗最重要的结局指标。
要点
- 肺纤维化患者中仅51%曾接受睡眠评估,未评估者75%主张常规纳入管理。
- 医护中64%常规或按临床指征进行睡眠评估,82%认为评估非常重要或有些重要。
- 双方最高研究优先事项为治疗夜间低氧血症对症状负担(含生活质量)的影响。
核心结论
- 研究提供了利益相关者对肺纤维化睡眠评估和夜间低氧血症治疗的研究优先事项见解,以指导未来研究。
研究设计与样本
- 国际混合方法在线调查后接在线焦点小组,纳入68例肺纤维化患者和73名擅长肺纤维化、睡眠医学和/或氧疗的医护人员,来自29个国家。
- 调查完整参与者中,14例患者和39名医护人员参加焦点小组。
主要发现
- 51%的肺纤维化患者曾接受睡眠评估;未评估者中75%主张将睡眠评估纳入常规肺纤维化管理。
- 64%的医护人员常规或按临床指征进行睡眠评估,82%报告评估非常重要或有些重要。
- 患者和医护人员均将治疗夜间低氧血症对症状负担(包括健康相关生活质量)的影响列为最高研究优先事项。
- 其他研究优先事项包括夜间氧疗的安全性和耐受性、对死亡率和肺动脉高压的影响、诊断方法、预测因素、用户友好设备及患者意识。
- 双方将健康相关生活质量列为评估夜间氧疗的最重要结局指标;患者高度排名FVC、呼吸暂停低通气指数和夜间氧合状态,医护选择生存和肺动脉高压发展。
临床怎么用
- 临床中应关注肺纤维化患者的睡眠评估和夜间低氧血症管理,多数未评估患者主张常规纳入。
- 医护人员可考虑将睡眠评估常规或按临床指征实施,并重视健康相关生活质量作为夜间氧疗的评估指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nocturnal hypoxemia commonly affects people with pulmonary fibrosis (PF). RESEARCH QUESTION: What are the current practices for assessment of sleep and nocturnal hypoxemia in PF, and what are the research priorities and outcome measures of importance for nocturnal oxygen therapy (NOT)? STUDY DESIGN AND METHODS: People with PF and health care professionals (HCPs) with expertise in PF, sleep medicine, and/or oxygen therapy, were recruited internationally to participate in mixed-methods online surveys followed by online focus groups. RESULTS: A total of 68 people with PF and 73 HCPs from 29 countries completed the survey, with 14 and 39 joining the focus groups, respectively. Of these, 51% of people with PF had previous sleep assessment. In those that had not, 75% advocated its inclusion in routine PF management. Of HCPs, 64% performed sleep assessments routinely or as clinically indicated, with 82% reporting the assessments as very or somewhat important. The effect of treating nocturnal hypoxemia on symptom burden (including health-related quality of life) was considered the top research priority for people with PF and HCPs. Other research priorities identified were safety and tolerability of NOT, effect of treating nocturnal hypoxemia on mortality and pulmonary hypertension, diagnostic approaches for assessing sleep and nocturnal hypoxemia, predictors of nocturnal hypoxemia, developing a user-friendly oxygen therapy device, and patient awareness of the significance of nocturnal hypoxemia. Both groups prioritized health-related quality of life as the most important outcome measure for evaluating NOT. Additionally, people with PF highly ranked FVC, apnea-hypopnea index, and nocturnal oxygenation status, whereas HCPs selected survival and development of pulmonary hypertension. People with PF raised impact of nocturnal hypoxemia and sleep disturbance on cognitive performance as a key research topic, which was agreed by HCPs. INTERPRETATION: This study provides important insights into stakeholders' priorities to guide future research on sleep assessment and treatment of nocturnal hypoxemia in PF.
引用
- Dowman L, Landry S, Smallwood N, et al. International Stakeholder Engagement on Clinical Care and Research for Sleep Assessment and Nocturnal Hypoxemia in Pulmonary Fibrosis. Chest. 2025. PMID: 41015202. doi:10.1016/j.chest.2025.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。